Sweden's Klaria Q1 loss widens on higher R&D expenses
Sweden's Klaria Q1 loss widens on higher R&D expenses
Overview
Sweden pharmaceutical developer's Q1 net sales dropped sharply yr/yr
Q1 loss widened to SEK 8.7 mln, with EPS at -0.04 SEK
R&D expenses rose to SEK 4.9 mln in the quarter
Outlook
Company did not provide specific guidance for the current quarter or full year
Result Drivers
HIGHER R&D SPENDING - R&D expenses increased to SEK 4.9 mln in Q1 from SEK 3.4 mln a year earlier
Company press release: ID:nWkr1dfkzx
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Sales |
| SEK 0.1 mln |
|
Q1 EPS |
| -SEK 0.04 |
|
Q1 Net Income |
| -SEK 8.7 mln |
|
Q1 Adjusted Free Cash Flow |
| -SEK 0.1 mln |
|
Analyst Coverage
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 40 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)